Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:28:24.767Z.
Calculation as of: 2026-10-06T16:28:24.767Z.
Quote observation: 2026-10-06T16:25:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 954f90b5803147d7e77bb33cb230df589f2ac0b2215919e8afc4fbf9605c1a4a
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Profound Medical Corp. (PROF) | $228.93M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $230.08M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $233.59M | N/A | 28.08 | 28.08 | 28.08 |
| BioAge Labs Inc. (BIOA)vs › | $232.72M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $221.87M | N/A | 26.24 | 26.24 | 26.24 |
| High Tide Inc. (HITI)vs › | $236.81M | N/A | N/A | N/A | N/A |
| SIGA Technologies, Inc. (SIGA)vs › | $238.23M | N/A | 10.01 | 8.82 | 11.38 |
| InflaRx N.V. (IFRX)vs › | $238.61M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $218.26M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $239.42M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
